Asian Pacific society of nephrology clinical practice guideline on diabetic kidney disease - executive summary

• Main Authors: Liew, Adrian, Bavanandan, Sunita, Prasad, Narayan, Wong, Muh Geot, Chang, Jer Ming, Eiam-Ong, Somchai, Hao, Chuan-Ming, Lim, Chiao Yuen, Lim, Soo Kun, Oh, Kook-Hwan, Okada, Hirokazu, Susantitaphong, Paweena, Lydia, Aida, Tran, Huong Thi Bich, Villanueva, Russell, Yeo, See Cheng, Tang, Sydney C. W.
• Format: Article
• Published: Wiley 2020
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/36368/

In the 2018 iteration of the United States Renal Data System (USRDS) report, 6 out of the top 10 countries in the world with diabetic kidney disease (DKD) as the cause of end-stage kidney disease (ESKD) were from the Asia-Pacific region, with Malaysia and Singapore topping the charts consistently over the previous years (1). It is, therefore, unsurprising that DKD is a significant healthcare burden for the Asia-Pacific countries, with a considerable amount of the countries’ medical expenditure being spent on kidney replacement therapy (KRT) (2). Specifically, the differences in healthcare infrastructure, resources and cultural beliefs among the Asia-Pacific countries have resulted in the heterogeneity of care and outcomes for people with DKD in the region. The Asian Pacific Society of Nephrology (APSN) consequently commissioned a Working Group (WG) to develop a set of clinical guidelines on the management of DKD, and in particular, to pay attention to nuances of health care across different countries in the region with the aim of making these guidelines applicable and implementable.